Phase II study of Radium‐223 dichloride combined with hormonal therapy for hormone receptor‐positive, bone‐dominant metastatic breast cancer

BACKGROUND: Radium‐223 dichloride (Ra‐223) is a targeted alpha therapy that induces localized cytotoxicity in bone metastases. We evaluated the efficacy and safety of Ra‐223 plus hormonal therapy in hormone receptor‐positive (HR+), bone‐dominant metastatic breast cancer. METHODS: In this single‐cent...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Med
Main Authors: Ueno, Naoto T., Tahara, Rie K., Fujii, Takeo, Reuben, James M., Gao, Hui, Saigal, Babita, Lucci, Anthony, Iwase, Toshiaki, Ibrahim, Nuhad K., Damodaran, Senthil, Shen, Yu, Liu, Diane D., Hortobagyi, Gabriel N., Tripathy, Debu, Lim, Bora, Chasen, Beth A.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2019
Assuntos:
Clinical Cancer Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6997080/
https://ncbi.nlm.nih.gov/pubmed/31849202
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2780
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares